B7-H3-targeting CAR-T cell therapy

N/A

Report date: 2024/05/24 20:00:45

Base Information

Drug NameB7-H3-targeting CAR-T cell therapy

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD276

TargetsCD276 antigen

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBeijing Tiantan Hospital, Capital Medical University

China Registration ClassN/A

Develop Information

Active CompaniesBeijing Tiantan Hospital, Capital Medical University

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A